Akari Therapeutics Reports $17.3 Million Net Loss for Fiscal Year 2025, Focuses on ADC Platform Development

Akari Therapeutics Plc has reported a net loss of $17.3 million for the fiscal year ending December 31, 2025, a decrease of 20% from the $21.6 million loss recorded in 2024. The reduction in losses is attributed primarily to the absence of merger-related expenses and restructuring costs that were significant in the previous year. Total operating expenses for 2025 amounted to $17.3 million, down from $21.6 million in 2024, with notable decreases in research and development expenses, which fell by 60% to $2.8 million, reflecting the company's strategic shift towards its antibody-drug conjugate (ADC) platform and the suspension of its legacy programs.

The company has made significant strides in advancing its lead product candidate, AKTX-101, which is currently in the preclinical stage. Akari is focusing on IND-enabling activities with the goal of initiating clinical trials by early 2027. The ADC platform utilizes a novel payload, PH1, which has shown promise in preclinical studies for targeting various cancers. Additionally, Akari has expanded its pipeline with AKTX-102, another ADC targeting CEACAM5, which is relevant for several solid tumors. The company has engaged WuXi Biologics/XDC for GMP manufacturing activities, marking a critical step in preparing for clinical trials.

As of December 31, 2025, Akari had cash reserves of approximately $5.2 million and an accumulated deficit of $264.5 million. The company has not yet generated any revenue from product sales and anticipates requiring substantial additional capital to fund ongoing operations and development activities. To address its financial needs, Akari has engaged in multiple financing initiatives, including a registered direct offering and private placements, which collectively raised approximately $8.7 million in gross proceeds in December 2025. However, the company has expressed concerns about its ability to continue as a going concern if it cannot secure additional funding.

Operationally, Akari has a small workforce, with only six employees as of March 1, 2026, which raises concerns about its capacity to manage and execute its development plans effectively. The company has also identified material weaknesses in its internal controls over financial reporting, which it is actively working to remediate. The management team is focused on enhancing its technical accounting resources and establishing additional review layers for complex transactions to ensure compliance with regulatory standards.

Looking ahead, Akari's future growth will depend on the successful development and commercialization of its product candidates, navigating regulatory approvals, and securing adequate funding. The company remains optimistic about its ADC platform's potential but acknowledges the inherent risks and uncertainties associated with drug development, including competition and market acceptance challenges.